Condition
Medium Vessel Occlusion clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Medium Vessel Occlusion clinical trials that are recruiting, at sites in 2 countries (most in China (4), United States (1)). By phase: Phase 3 (2), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Medium Vessel Occlusion clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Promising Management of Medium Vessel Occlusion in Ischemic Stroke: Real-World Registry | — | Indianapolis, Indiana | Recruiting | Aug 5, 2026 |
| Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion | Phase 3 | Nanjing, Jiangsu | Recruiting | Jun 25, 2026 |
| Tenecteplase delivered into the artery for acute medium-vessel stroke | Phase 3 | Beijing, Beijing Municipality | Recruiting | Jan 22, 2026 |
| Intra-arterial tenecteplase for medium-vessel occlusion stroke | Phase 2/3 | Wuhan, Hubei | Recruiting | Dec 24, 2025 |
| Intra-arterial clot-dissolving treatment for medium-vessel ischemic stroke | — | Fuyang, Anhui and 5 other locations | Recruiting | Sep 22, 2025 |
All recruiting trials (5)
-
Promising Management of Medium Vessel Occlusion in Ischemic Stroke: Real-World Registry
This study tests how MeVO-related stroke is managed in real-world practice across multiple U.S. centers, including both medical therapy and mechanical interventions.
-
Intra-arterial Thrombolysis for Acute Ischemic Stroke with Medium Vessel Occlusion
This trial tests whether delivering a clot-busting medicine directly into the brain’s medium vessels helps improve outcomes for adults with acute ischemic stroke caused by MeVO, on top of standard care.
-
Tenecteplase delivered into the artery for acute medium-vessel stroke
This trial will test whether giving tenecteplase directly into the blocked artery helps adults with acute medium-vessel ischemic stroke recover better when treated within 24 hours.
-
Intra-arterial tenecteplase for medium-vessel occlusion stroke
This trial will test whether delivering tenecteplase directly into the blocked medium brain artery helps adults with medium-vessel ischemic stroke recover better when treated within 24 hours of symptom onset.
-
Intra-arterial clot-dissolving treatment for medium-vessel ischemic stroke
The team will test whether giving tenecteplase directly into the artery helps adults with acute ischemic stroke caused by medium-vessel blockage or severe narrowing.
Related topics
Quick answers
How many Medium Vessel Occlusion clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (4 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.